323 related articles for article (PubMed ID: 27225450)
1. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
[TBL] [Abstract][Full Text] [Related]
2. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
3. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.
Eloy JO; Petrilli R; Topan JF; Antonio HMR; Barcellos JPA; Chesca DL; Serafini LN; Tiezzi DG; Lee RJ; Marchetti JM
Colloids Surf B Biointerfaces; 2016 May; 141():74-82. PubMed ID: 26836480
[TBL] [Abstract][Full Text] [Related]
4. Antibody-conjugated pH-sensitive liposomes for HER-2 positive breast cancer: development, characterization,
Raikwar S; Yadav V; Jain S; Jain SK
J Liposome Res; 2024 Jun; 34(2):239-263. PubMed ID: 37594466
[TBL] [Abstract][Full Text] [Related]
5. Effect of lipid composition on incorporation of trastuzumab-PEG-lipid into nanoliposomes by post-insertion method: physicochemical and cellular characterization.
Golkar N; Tamaddon AM; Samani SM
J Liposome Res; 2016; 26(2):113-25. PubMed ID: 26023889
[TBL] [Abstract][Full Text] [Related]
6. Targeted co-delivery of polypyrrole and rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy.
Nguyen HT; Tran TH; Thapa RK; Phung CD; Shin BS; Jeong JH; Choi HG; Yong CS; Kim JO
Int J Pharm; 2017 Jul; 527(1-2):61-71. PubMed ID: 28528212
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.
Yang T; Choi MK; Cui FD; Lee SJ; Chung SJ; Shim CK; Kim DD
Pharm Res; 2007 Dec; 24(12):2402-11. PubMed ID: 17828616
[TBL] [Abstract][Full Text] [Related]
8. Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.
Vaidya T; Straubinger RM; Ait-Oudhia S
Pharm Res; 2018 Mar; 35(5):95. PubMed ID: 29536232
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel.
Raju A; Muthu MS; Feng SS
Expert Opin Drug Deliv; 2013 Jun; 10(6):747-60. PubMed ID: 23458409
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.
Rodallec A; Brunel JM; Giacometti S; Maccario H; Correard F; Mas E; Orneto C; Savina A; Bouquet F; Lacarelle B; Ciccolini J; Fanciullino R
Int J Nanomedicine; 2018; 13():3451-3465. PubMed ID: 29950829
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy.
Parhi P; Sahoo SK
J Colloid Interface Sci; 2015 Aug; 451():198-211. PubMed ID: 25897856
[TBL] [Abstract][Full Text] [Related]
12. Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells.
Catania A; Barrajón-Catalán E; Nicolosi S; Cicirata F; Micol V
Breast Cancer Res Treat; 2013 Aug; 141(1):55-65. PubMed ID: 23959397
[TBL] [Abstract][Full Text] [Related]
13. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells.
Varshosaz J; Davoudi MA; Rasoul-Amini S
J Liposome Res; 2018 Dec; 28(4):285-295. PubMed ID: 28826287
[TBL] [Abstract][Full Text] [Related]
15. Fusogenic pH sensitive liposomal formulation for rapamycin: improvement of antiproliferative effect.
Ghanbarzadeh S; Khorrami A; Mohamed Khosroshahi L; Arami S
Pharm Biol; 2014 Jul; 52(7):848-54. PubMed ID: 24920230
[TBL] [Abstract][Full Text] [Related]
16. Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3).
Rodallec A; Sicard G; Giacometti S; Carre M; Maia T; Valette M; Bouquet F; Savina A; Lacarelle B; Ciccolini J; Fanciullino R
Anticancer Drugs; 2020 Jun; 31(5):463-472. PubMed ID: 31895102
[TBL] [Abstract][Full Text] [Related]
17. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
18. Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
Narayanaswamy R; Torchilin VP
Pharm Res; 2021 Mar; 38(3):429-450. PubMed ID: 33655395
[TBL] [Abstract][Full Text] [Related]
19. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
20. From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.
Rodallec A; Sicard G; Giacometti S; Carré M; Pourroy B; Bouquet F; Savina A; Lacarelle B; Ciccolini J; Fanciullino R
Int J Nanomedicine; 2018; 13():6677-6688. PubMed ID: 30425482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
